The effect of diprydamole on flow-mediated dilatation in patients with slow coronary flow

Amaç: Yavaş koroner akım (YKA), anjiyografık olarak belirgin koroneir arter hastalığı1 yokluğunda, Thrombolysis in Myocardial Infarction (TIMI)-2 akımın izlendiği farkı bir anjiyografik bulğu olup patofizyolojisi ile ilgili olarak endotel ve mikrovasküler disfonksiyon üzerinde durulmaktadır. Önceki çalışmalarda oral başlanan: dipridamolün-anjiyografik olarak YKA'ı düzelttiği gösterilmiştir. Bu çalışmanın amacı;fizyopatolojisinde endotel disfonksiyonunun düşünüldüğü YKA'da, dipridamolün endotel fonksiyonları üzerine olan etkisini değerlendirmektir. Gereç ve yöntem: Çalışmaya anjiyografık olarak bir veya daha fazla koroner arterinde yavaş akımın tespit edildiği, 28 hasta (ortalama yaşları 50 ± 8.0 olan 22 erkek 6 kadın) alındı. Çalışmaya katılan hastalarda endotel fonksiyonlarını , etkileyebilecek olan ilaçlar 15 gün öncesinden kesildi. 15. gün sonunda bazal brakiyal arter Doppler incelemesi , yapıldıktan sonra hastalara 1 ay süre ile 75 mg dipridamol günde 3 defa verildi ve 1. ay sonunda brakiyal arter Doppler incelemesi tekrarlandı. Bulgular: Hastaların dipridamol öncesi ve sonrası değerleri karşılaştırıldığında bazal akım aracılı vazodilatasyon (AAD) % değerine göre dipridamol sonrası bakılan % AAD değerinde anlamlı artış izlendi (AAD dipridamol öncesi: %2.7±1.9, AAD dipridamol sonrası; %3.:1 + 1:8, p=0.001). Nitrogliserin (N.TG), yani endotel bağımsız dilatasyonda , dipridamol öncesi ve: sonrası açısından, farklılık, tespit edilmedi (NTG dipiridamo] öncesi: %13.1 ±3.3, NTG dipiridamol sonrası: %13.0±3.0, p=0.9). Ortalama, düzeltilmiş TIMI frame sayısının bazal-AAD yüzdesi ile güçlü fakat : ters bir ilişkigösterdiği belirlendi. (r=-0.26, p<0.05) Sonuç: YKA'lı hastalarjda dipridamol, endotel disfonksiyonuna bağlı olarak gelişen bozulmuş AAD üzerine olumlu etki gösterir.Aim: The slow coronary flow (SCF), a distinct angiographic finding characterized by presence of Thrombolysis in Myocardial Infarction (TIMI) -2 flow in the absence of coronary disease, pathophysiologically related to endothelial' and microvascular dysfunction. Previous studies, it has been shown that oral diprydamole could correct the SCF angiographically. The aim of this study is to evaluate the effect of diprydamole on endothelial; functions tested from the forearm, SCF which is physiopathologically related to endothelial dysfunction. Material and methods: 28 patients (22 male, 6 female, mean age 50&plusmn;8.0) with angiographicalfy-proyen slow coronary flow at one or more coronary arterieswere included in study. All drugs that may interact with'endothelial functions were stopped 15 days before the study. At the end of 15 days, baseline brachial artery Doppler'exairiinations were performed and diprydamole 75 mg tid. was given to all patients during the nex tone month, and at the end of one month, brachial artery Doppler examinations were reperformed. Results: When the results of the patients before and after use of diprydamole were compared, it was observed that * post-diprydamole flow mediated vasodilatation (FMD) value was significantly higher than the basal FMD value (FMD-prediprydamole: 2.7%&plusmn;1.9, FMD-postdiprydamole: 3.1%&plusmn;1.8, p=0.001). Nitroglyserine (NTG), thus shows . endothelium-independent vasodilatation, showed no significant, difference in prediprydamole and postdiprydamole period (NTG-prediprydamole: 13.1%&plusmn;3.3, NTG-postdiprydamole: 13.0%&plusmn;3.0, p=0.9). It was also noted that mean corrected TIMI frame count showed strong but inverse relationship with baseline F1V&Icirc;D percent (r&amp;#8212;0.26, p&lt;0.05). Conclusion: In patients with SCF, diprydamole improves FMD related to endothelial dysfunction

Sensitive analysis of simazine based on platinum nanoparticles on polyoxometalate/multi-walled carbon nanotubes

Atar, Necip/0000-0001-8779-1412WOS: 000373096500003PubMed: 26928060In this report, a novel molecular imprinted voltammetric sensor based on glassy carbon electrode (GCE) modified with platinum nanoparticles (PtNPs) involved in a polyoxometalate (H3PW12O40, POM) functionalized multi -walled carbon nanotubes (MWCNs) sheets was prepared for the determination of simazine (SIM). The developed surfaces were characterized by using scanning electron microscopy (SEM), transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS) and X-ray diffraction (XRD) method. SIM imprinted GCE was prepared via electropolymerization process of 100 mM pyrrole as monomer in the presence of 0.1 M acetate buffer (pH 4.0) containing 25 mM SIM. The linearity range and the detection limit of the developed method were calculated as 1.0 x 10(-19)-5.0 x 10(-9) M and 2.0 x 10(-11) M, respectively. In addition, the voltammetric sensor was applied to wastewater samples. The stability and reproducibility of the voltammetric sensor were also reported. (C) 2016 Elsevier Inc. All rights reserved

Coronary collateral circulation: Any effect on P-wave dispersion?

Coronary collateral circulation determines the severity of ischemic myocardial damage. Increased P-wave dispersion is an independent predictor for atrial fibrillation. Consistent evidence is little about the relation between coronary collateral circulation and arrhythmia risk. In this article, the effect of coronary collateral circulation on P-wave dispersion was evaluated. Collateral grade and p-wave dispersion were ascertained in 100 patients with >= 85% diameter stenoses in left anterior descending or right coronary arteries. Left ventricular function score was also determined in all patients. Coronary collateral circulation was absent in 32 patients, whereas 68 patients had coronary collateral circulation. Patients with collateral grade A had greater left ventricular function score than did patients with collateral grade 0 (P = .048). However, there was no significant difference between P-wave dispersion of patients with and without coronary collateral circulation (P = .45). The presence of coronary collateral circulation failed to exert a beneficial decreasing effect on P-wave dispersion

The Frequency of Fabry Disease in Patients with Cardiac Hypertrophy of Various Phenotypes Including Prominent Papillary Muscle: The TUCARFAB Study in Turkey

BACKGROUND: The present study aimed to identify the frequency of Fabry disease in patients with cardiac hypertrophy of unknown etiology and to evaluate demographic and clinical characteristics, enzyme activity levels, and genetic mutations at the time of diagnosis. METHODS: This national, multicenter, cross-sectional, single-arm, observational registry study was conducted in adult patients with a clinical echocardiographic diagnosis of left ventricular hypertrophy and/or the presence of prominent papillary muscle. In both genders, genetic analysis was performed by DNA Sanger sequence analysis. RESULTS: A total of 406 patients with left ventricular hypertrophy of unknown origin were included. Of the patients, 19.5% had decreased enzyme activity (≤2.5 nmol/mL/h). Although genetic analysis revealed GLA (galactosidase alpha) gene mutation in only 2 patients (0.5%), these patients were considered to have probable but not 'definite Fabry disease' due to normal lyso Gb3 levels and gene mutations categorized as variants of unknown significance. CONCLUSION: The prevalence of Fabry disease varies according to the characteristics of the population screened and the definition of the disease used in these trials. From cardiology perspective, left ventricular hypertrophy is the major reason to consider screening for Fabry disease. Enzyme testing, genetic analysis, substrate analysis, histopathological examination, and family screening should be performed, when necessary, for a definite diagnosis of Fabry disease. The results of this study underline the importance of the comprehensive use of these diagnostic tools to reach a definite diagnosis. The diagnosis and management of Fabry disease should not be based solely on the results of the screening tests

Preliminary Results From a Nationwide Adult Cardiology Perspective for Pulmonary Hypertension: Registry on Clinical Outcome and Survival in Pulmonary Hypertension Groups (Simurg)

Objective: The present study was designed to evaluate the characteristics of pulmonary hypertension (PH) and adult cardiology practice patterns for PH in our country. Methods: We evaluated preliminary survey data of 1501 patients with PH (females, 69%; age, 44.8±5.45) from 20 adult cardiology centers (AdCCs). Results: The average experience of AdCCs in diagnosing and treating patients with PH was 8.5±3.7 years. Pulmonary arterial hypertension (PAH) was the most frequent group (69%) followed by group 4 PH (19%), group 3 PH (8%), and combined pre- and post-capillary PH (4%). PAH associated with congenital heart disease (APAH-CHD) was the most frequent subgroup (47%) of PAH. Most of the patients’ functional class (FC) at the time of diagnosis was III. The right heart catheterization (RHC) rate was 11.9±11.6 per month. Most frequently used vasoreactivity agent was intravenous adenosine (60%). All patients under targeted treatments were periodically for FC, six-minute walking test, and echo measures at 3-month intervals. AdCCs repeated RHC in case of clinical worsening (CW). The annual rate of hospitalization was 14.9±19.5. In-hospital use of intravenous iloprost reported from 16 AdCCs in CWs. Bosentan and ambrisentan, as monotreatment or combination treatment (CT), were noted in 845 and 28 patients, respectively, and inhaled iloprost, subcutaneous treprostinil, and intravenous epoprostenol were noted in 283, 30, and four patients, respectively. Bosentan was the first agent used for CT in all AdCCs and iloprost was the second. Routine use of antiaggregant, anticoagulant, and pneumococcal and influenza prophylaxis were restricted in only two AdCCs. Conclusion: Our nationwide data illustrate the current status of PH regarding clinical characteristics and practice patterns.PubMedWoSScopu

Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clInical outcoMe and sUrvival in pulmonaRy hypertension Groups (SIMURG)

Objective: The present study was designed to evaluate the characteristics of pulmonary hypertension (PH) and adult cardiology practice patterns for PH in our country